Ionis Pharmaceuticals (IONS) Return on Capital Employed (2010 - 2026)

Ionis Pharmaceuticals' Return on Capital Employed history runs 17 years deep, the most recent figure standing at 12.72% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 506.0% year-over-year to 12.72% in Q1 2026; TTM through Mar 2026 was 12.72%, a 506.0% increase from a year earlier, with the FY2025 full-year figure at 15.38%, up 230.0% from the prior year.
• Return on Capital Employed rose to 12.72% in Q1 2026 per IONS's latest filing, from 15.29% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 0.86% in Q3 2022 and bottomed at 21.8% in Q3 2023.
• The 5-year median for Return on Capital Employed is 15.07% (2024), against an average of 13.26%.
• Across the five-year window, Return on Capital Employed surged 1342 bps in 2022 and slumped 2266 bps in 2023, its largest moves.
• Year by year, Return on Capital Employed stood at 18.93% in 2022, then climbed by 26 bps to 14.07% in 2023, then declined by 24 bps to 17.38% in 2024, then gained by 12 bps to 15.29% in 2025, then climbed by 17 bps to 12.72% in 2026.
• Per Business Quant, the three latest IONS Return on Capital Employed figures stand at 12.72% (Q1 2026), 15.29% (Q4 2025), and 13.2% (Q3 2025).